Yu et al. [79] obtained through molecular biology and network pharmacology analysis that the core targets of SSM formula in the treatment of liver cancer included MAPK1, JUN, HSP90AA1, TP53, EGFR, and AR, and after SSM treatment, the vitality and migration of liver cancer cells were reduced, and apoptosis was further promoted. This evidence concerns the gene MAPK1 and liver cancer.